Outcome and management of hepatitis C in liver transplant recipients

被引：14

作者：

Chan, SE ^{[1
]}

Rosen, HR ^{[1
]}

机构：

[1] Portland VA Med Ctr, Div Gastroenterol Hepatol, Portland, OR 97207 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 06期

关键词：

D O I：

10.1086/377605

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hepatitis C virus (HCV)- related cirrhosis is the leading indication for liver transplantation. Reinfection of the allograft with HCV is universal in all patients with pretransplantation viremia, and leads to histologically proven hepatitis in 50% - 80% of these patients. Recent data have demonstrated significantly higher mortality among HCV-positive liver transplant recipients. For this subgroup of patients, retransplantation remains highly controversial. As current antiviral therapy is limited in efficacy and tolerability, an improved understanding of those patients at greatest risk of developing serious HCV-induced graft injury is necessary to optimize treatment.

引用

页码：807 / 812

页数：6

共 37 条

[1] Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin [J].

Ahmad, J ;

Dodson, SF ;

Demetris, AJ ;

Fung, JJ ;

Shakil, AO .

LIVER TRANSPLANTATION, 2001, 7 (10) :863-869

[2] Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study [J].

Alberti, AB ;

Belli, LS ;

Airoldi, A ;

de Carlis, L ;

Rondinara, G ;

Minola, E ;

Vangeli, M ;

Cernuschi, A ;

D'Amico, M ;

Forti, D ;

Pinzello, G .

LIVER TRANSPLANTATION, 2001, 7 (10) :870-876

[3] Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation [J].

Baron, PW ;

Sindram, D ;

Higdon, D ;

Howell, DN ;

Gottfried, MR ;

Tuttle-Newhall, JE ;

Clavien, PA .

LIVER TRANSPLANTATION, 2000, 6 (04) :407-412

[4] Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis [J].

Berenguer, M ;

Prieto, M ;

Palau, A ;

Rayón, J ;

Carrasco, D ;

San Juan, F ;

López-Labrador, FX ;

Moreno, R ;

Mir, J ;

Berenguer, J .

LIVER TRANSPLANTATION, 2003, 9 (03) :228-235

[5] Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation [J].

Berenguer, M ;

Prieto, M ;

Rayón, JM ;

Mora, J ;

Pastor, M ;

Ortiz, V ;

Carrasco, D ;

San Juan, F ;

Burgueño, MDJ ;

Mir, J ;

Berenguer, J .

HEPATOLOGY, 2000, 32 (04) :852-858

[6] Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients [J].

Berenguer, M ;

Prieto, M ;

San Juan, F ;

Rayón, JM ;

Martinez, F ;

Carrasco, D ;

Moya, A ;

Orbis, F ;

Mir, J ;

Berenguer, J .

HEPATOLOGY, 2002, 36 (01) :202-210

[7] HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].

Berenguer, M ;

Ferrell, L ;

Watson, J ;

Prieto, M ;

Kim, M ;

Rayón, M ;

Córdoba, J ;

Herola, A ;

Ascher, N ;

Mir, J ;

Berenguer, J ;

Wright, TL .

JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684

[8] Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [J].

Bizollon, T ;

Palazzo, U ;

Ducerf, C ;

Chevallier, M ;

Elliott, M ;

Baulieux, J ;

Pouyet, M ;

Trepo, C .

HEPATOLOGY, 1997, 26 (02) :500-504

[9] Pre-emptive treatment of recurrent hepatitis C infection [J].

Charlton, M .

LIVER TRANSPLANTATION, 2002, 8 (10) :S50-S54

[10] Predictors of patient and graft survival following liver transplantation for hepatitis C [J].

Charlton, M ;

Seaberg, E ;

Wiesner, R ;

Everhart, J ;

Zetterman, R ;

Lake, J ;

Detre, K ;

Hoofnagle, J .

HEPATOLOGY, 1998, 28 (03) :823-830

← 1 2 3 4 →